Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29800504 | 1.00 | KMT2A (0.47) | KMT2ATLR2FABP5FABP7DPP7 | |
| SCHEMBL8575036 | 0.87 | KMT2A (0.49) | KMT2ATLR2FABP5FABP7DPP7 | |
| SCHEMBL5577296 | 0.87 | KMT2A (0.49) | KMT2ATLR2FABP5FABP7DPP7 | |
| Hydrochloric Acid SCHEMBL6518503 | 0.87 | KMT2A (0.49) | KMT2ATLR2FABP5FABP7DPP7 | |
| Hydrochloric Acid SCHEMBL13858072 | 0.86 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7DPP7 | |
| SCHEMBL31720760 | 0.85 | KMT2A (0.61) | KMT2ATLR2DPP7DPP8DPP9 | |
| SCHEMBL16491962 | 0.84 | KMT2A (0.47) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL17941346 | 0.84 | KMT2A (0.51) | KMT2ATLR2FABP5FABP7DPP7 | |
| SCHEMBL3842242 | 0.84 | KMT2A (0.46) | KMT2ATLR2FABP5FABP7DPP7 | |
| SCHEMBL15424391 | 0.84 | KMT2A (0.50) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344134-B1 | NANOCARRIERS FOR DRUG DELIVERY | UNIV CALIFORNIA (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20170290921-A1 | NANOCARRIERS FOR DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170218017-A1 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE | H LEE MOFFITT CANCER CT & RES (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170189531-A1 | COMPOSITION AND METHODS FOR TETHERING BIOACTIVE PEPTIDES TO METAL OXIDE SURFACES | THE UNIVERSITY OF AKRON (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
| US-9579400-B2 | Nanocarriers for drug delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-28 | — | — | US | disclosed |
| US-9539301-B2 | Melanotropin ligands for skin care | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-01-10 | — | — | US | disclosed |
| WO-2017004144-A1 | ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER | IMMUNOMEDICS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| US-20160303253-A1 | ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER | JOHNSON MATTHEY PHARMACEUTICAL MATERIALS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-9441013-B2 | Melanocortin 1 receptor ligands and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150038672-A1 | Modular Imaging Agents Containing Amino Acids and Peptides | ROCHESTER INSTITUTE OF TECHNOLOGY (US) | 2015-02-05 | — | — | US | disclosed |
| US-20140377212-A1 | CONFORMATIONS OF DIVERGENT PEPTIDES WITH MINERAL BINDING AFFINITY | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-12-25 | — | — | US | disclosed |
| US-8889828-B2 | Conformations of divergent peptides with mineral binding affinity | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-11-18 | — | — | US | disclosed |
| WO-2014081886-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140112873-A1 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| WO-2013029340-A9 | BIOCOMPATIBLE NANOPARTICLES WITH AGGREGATION INDUCED EMISSION CHARACTERISTICS AS FLUORESCENT BIOPROBES AND METHODS OF USING THE SAME FOR IN VITRO AND IN VIVO IMAGING | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2013-07-11 | — | — | WO | disclosed |
| US-8466107-B2 | Fibrin-binding peptides and conjugates thereof | BRACCO IMAGING SPA (IT) | 2013-06-18 | — | — | US | disclosed |
| US-20130121917-A1 | Lipid-Peptide-Polymer Conjugates and Nanoparticles Thereof | LAWRENCE BERKELEY NATIONAL LABORATORY (US) | 2013-05-16 | — | — | US | disclosed |
| US-20120328512-A1 | Fibrin-Binding Peptides and Conjugates Thereof | BRACCO IMAGING S.P.A. (IT) | 2012-12-27 | — | — | US | disclosed |
| US-8278274-B2 | Fibrin-binding peptides and conjugates thereof | BRACCO IMAGING SPA (IT) | 2012-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290921-A1 | NANOCARRIERS FOR DRUG DELIVERY | CLTA, EPCAM, EGFR | KMT2A 3624/4885TLR2 719/4885FABP5 451/4885 |
| US-20150038672-A1 | Modular Imaging Agents Containing Amino Acids and Peptides | SLC43A1, TAP1, TTR | KMT2A 1695/4885TLR2 2008/4885FABP5 257/4885 |
| US-20170218017-A1 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE | MC1R, MC3R, MC5R | KMT2A 2734/4885TLR2 452/4885FABP5 1219/4885 |
| US-20160303253-A1 | ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER | CLTA, CLTC, FCGR2A | KMT2A 667/4885TLR2 1615/4885FABP5 3414/4885 |
| US-20140377212-A1 | CONFORMATIONS OF DIVERGENT PEPTIDES WITH MINERAL BINDING AFFINITY | SDF4, CALCB, CALCA | KMT2A 4667/4885TLR2 4385/4885FABP5 158/4885 |
| US-20140112873-A1 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE | MC1R, MC3R, MC5R | KMT2A 2734/4885TLR2 452/4885FABP5 1219/4885 |
| US-20120328512-A1 | Fibrin-Binding Peptides and Conjugates Thereof | FGB, F13B, F13A1 | KMT2A 4497/4885TLR2 4684/4885FABP5 104/4885 |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | KMT2A 3810/4885TLR2 3924/4885FABP5 2398/4885 |
| US-20170189531-A1 | COMPOSITION AND METHODS FOR TETHERING BIOACTIVE PEPTIDES TO METAL OXIDE SURFACES | PTMS, CALCB, CALCA | KMT2A 2602/4885TLR2 4397/4885FABP5 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.